Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the

Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada, BMC Cancer

1694-Melanoma metastatic ipilimumab and nivolumab (induction)

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study - The Lancet Oncology

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study - The Lancet Oncology

MBM - Melanoma Brain Metastases

Perspective on the Use of Nivolumab Combined with Ipilimumab For Advanced Melanoma

Considerations for First-Line Metastatic Melanoma: Which Treatment Is Best?

Updated Data for First-Line Immunotherapy Combinations Reinforce Their Value in Metastatic Melanoma

Cancers, Free Full-Text

Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study - European Journal of Cancer